In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci

被引：8
作者：
Farrell, David J.
Krause, Kevin M. [1 ]
Benton, Bret M. [1 ]
机构：
[1] Theravance Inc, San Francisco, CA USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2011年 / 69卷 / 03期
关键词：
Staphylococcus aureus; Telavancin; In vitro activity; GRAM-POSITIVE BACTERIA; MURINE MODEL; AUREUS; SURVEILLANCE; RESISTANCE; PNEUMONIA; EFFICACY; TD-6424; PCR;
D O I：
10.1016/j.diagmicrobio.2010.09.017
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The in vitro activity of telavancin was determined for 94 diverse Staphylococcus spp. Telavancin had MIC(90) values of 0.5 mu g/mL for methicillin-susceptible, methicillin-resistant, and vancomycin-susceptible Staphylococcus aureus, and coagulase-negative staphylococci isolates. Telavancin MICs were 0.5-1 mu g/mL for vancomycin-intermediate S. aureus isolates and 2-4 mu g/mL for vancomycin-resistant S. aureus strains. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码：275 / 279
页数：5
相关论文
共 18 条
[1]   Emergence of vancomycin-resistant enterococci in Australia: Phenotypic and genotypic characteristics of isolates [J].
Bell, JM ;
Paton, JC ;
Turnidge, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (08) :2187-2190
[2]   High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa:: Results from SENTRY antimicrobial surveillance program, 1998-1999 [J].
Bell, JM ;
Turnidge, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :879-881
[3]   National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 [J].
Cardo, D ;
Horan, T ;
Andrus, M ;
Dembinski, M ;
Edwards, J ;
Peavy, G ;
Tolson, J ;
Wagner, D .
AMERICAN JOURNAL OF INFECTION CONTROL, 2004, 32 (08) :470-485
[4]  
*CLSI, 2006, M7 A7 METH DIL ANT S
[5]   Vancomycin resistance in gram-positive cocci [J].
Courvalin, P .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S25-S34
[6]   In vitro activity of telavancin against recent Gram-positive clinical isolates:: results of the 2004-05 Prospective European Surveillance Initiative [J].
Draghi, Deborah C. ;
Benton, Bret M. ;
Krause, Kevin M. ;
Thornsberry, Clyde ;
Pillar, Chris ;
Sahm, Daniel F. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (01) :116-121
[7]   Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States [J].
Draghi, Deborah C. ;
Benton, Bret M. ;
Krause, Kevin M. ;
Thornsberry, Clyde ;
Pillar, Chris ;
Sahm, Daniel F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2383-2388
[8]   Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes [J].
Francis, JS ;
Doherty, MC ;
Lopatin, U ;
Johnston, CP ;
Sinha, G ;
Ross, T ;
Cai, M ;
Hansel, NN ;
Perl, T ;
Ticehurst, JR ;
Carroll, K ;
Thomas, DL ;
Nuermberger, E ;
Bartlett, JG .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (01) :100-107
[9]   Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria [J].
Hegde, SS ;
Reyes, N ;
Wiens, T ;
Vanasse, N ;
Skinner, R ;
McCullough, J ;
Kaniga, K ;
Pace, J ;
Thomas, R ;
Shaw, JP ;
Obedencio, G ;
Judice, JK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3043-3050
[10]   In vitro activity of telavancin against resistant gram-positive bacteria [J].
Krause, Kevin M. ;
Renelli, Marika ;
Difuntorum, Stacey ;
Wu, Terry X. ;
Debabov, Dmitri V. ;
Benton, Bret M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2647-2652
12